Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Chemokine, Granulocyte chemotactic protein-2 (GCP-2), Melanoma, GRANULOCYTE CHEMOTACTIC PROTEIN-2, CXC CHEMOKINE GCP-2/CXCL6, CELL LUNG-CANCER, EPITHELIAL-CELLS, UP-REGULATION, TUMOR-GROWTH, MALIGNANT-MELANOMA, EXPRESSION, INTERLEUKIN-8, ANGIOGENESIS, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Cell Line, Tumor, Cell Proliferation, Chemokine CXCL6, Chemotaxis, Leukocyte, Female, Granulocytes, Humans, Melanoma, Experimental, Mice, Mice, Inbred Strains, Mice, Nude, Neoplasm Metastasis, Xenograft Model Antitumor Assays, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases.